Both seladelpar (PPAR-δ agonist) and elafibranor (PPAR α/δ agonist) were granted accelerated FDA-approved as well as authorization by the European Commission for the treatment of PBC; phase 3 trials have demonstrated significant improvement in biochemical response and are generally well tolerated with seladelpar also being associated with reduced pruritus (Hirschfield et al., 2024; Kowdley et al., 2024). The gene discussed is PPARA; the disease is primary biliary cholangitis.